演題詳細

一般口演 / Oral Session

一般口演 100 (Oral Session 100) :節外性B細胞リンパ腫

print

日程
2013年10月13日(日)
時間
15:00 - 16:00
会場
第8会場 / Room No.8 (ロイトン札幌 2F ハイネス)
座長・司会
正木 康史 (Yasufumi Masaki):1
1:金沢医科大学 血液免疫内科学
 
前へ戻る

Comparison of clinical features between primary and secondary breast diffuse large B cell lymphoma

演題番号 : OS-3-146

高橋 寛行 (Hiroyuki Takahashi):1、高崎 啓孝 (Hirotaka Takasaki):1、岸本 久美子 (Kumiko Kishimoto):2、山本 恵理 (Eri Yamamoto):3、小山 哲 (Satoshi Koyama):4、板橋 めぐみ (Megumi Itabashi):4、石橋 大輔 (Daisuke Ishibashi):5、松浦 史郎 (Shiro Matsuura):6、渡辺 玲奈 (Reina Watanabe):1,7、立花 崇孝 (Takayoshi Tachibana):2、大島 理加 (Rika Ohshima):7、橋本 千寿子 (Chizuko Hashimoto):8、山崎 悦子 (Etsuko Yamazaki):3、小原澤 英之 (Hideyuki Koharazawa):8、竹村 佐千哉 (Sachiya Takemura):9、田口 淳 (Jun Taguchi):4、藤巻 克通 (Katsumichi Fujimaki):7、富田 直人 (Naoto Tomita):3、藤田 浩之 (Hiroyuki Fujita):6、藤澤 信 (Shin Fujisawa):2、本村 茂樹 (Shigeki Motomura):1、石ヶ坪 良明 (Yoshiaki Ishigatsubo):3、酒井 リカ (Rika Sakai):1

1:Dept. of Med. Oncol. Kanagawa Cancer Center, Yokohama, Japan、2:Department of Hematology, Yokohama City University Medical Center, Yokohama, Japan、3:Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan、4:Department of Hematology, Shizuoka Red Cross Hospital, Shizuoka, Japan、5:Department. of Hematology, Yokosuka City Hospital, Yokosuka, Japan、6:Department of Hematology, Saiseikai Yokohama Nanbu Hospital、7:Department of Hematology/Immunology, Fujisawa City Hospital、8:Department of Hematology, Yamato Municipal Hospital、9:Department of Internal Medicine, Yokohama Ekisaikai Hospital

 

Introduction/Background:Primary breast lymphoma (PBL) is defined as breast ± ipsilateral axial node involvement and reported to have better prognosis than others with breast lesion which is defined as secondary breast lymphoma (SBL). We compared clinical features and prognosis among PBL, limited stage SBL (LSBL), and advanced stage SBL (ASBL).
Patients and Methods:We retrospectively reviewed 25 DLBCL patients with breast involvement (among 1264 DLBCL patients) diagnosed by breast tumor biopsy who received chemotherapy at 9 hospitals between January 2000 and August 2012. DLBCL was diagnosed by the pathologists of each institution.
Results:The median age was 60 (range, 41-87) years, with 11 PBL, 6 LSBL, and 8 ASBL. The PBL group had significantly less patients with breast tumors (BT) >5 cm than the SBL group (1 vs. 8, P = 0.02) and significantly fewer had ≥2 extranodal sites than in the ASBL group (1 vs. 7, P = 0.03). After median follow-up of 44 (range, 8-141) months, 3-year overall survival (OS) for PBL, LSBL, ASBL was 75.0%, 50.0%, and 57.1%, respectively. The PBL group had significantly better OS than the LSBL group (P = 0.02), but there was no correlation with progression free survival (PFS). Patients with BT ≤5 cm had better OS (91.7%, 53.3%, P = 0.002) and PFS (92.3%, 30.0%, P = 0.003) than those with BT >5 cm.
Conclusion:PBL may have a better prognosis than SBL among limited stage DLBCL, possibly due to the impact of tumor size >5 cm, which was previously reported as a poor prognostic factor. To determine further prognostic impact of PBL, more data should be accumulated.

前へ戻る